Figure 1. Factor B ASO effectively reduces hepatic factor B mRNA and plasma factor B of normal mice. C57BL/6J mice were treated for 6 weeks with the indicated weekly doses of factor B antisense oligonucleotide (ASO) via subcutaneous injection (n = 4 per group). A: Study design. B: Dose-dependent reduction in hepatic factor B mRNA after subcutaneous administration of factor B ASO. C: ED₅₀ of hepatic factor B mRNA reduction by mouse factor B ASO. D: Ocular factor B mRNA level. E: Dose-dependent reduction in plasma factor B protein levels after the administration of the factor B ASO. F: Factor B protein level was measured with western blot with anti-factor B antibody. Quantification of the western blot using Image J. Factor B band intensity was normalized to the level of plasma immunoglobulin G (IgG). Results represent mean ± standard error of the mean (SEM). *p<0.05; one-way ANOVA with Tukey honest significant difference (HSD) multiple comparisons. G: Correlation between liver factor B mRNA level and plasma factor B protein level of mice after treatment with the factor B ASO. The Pearson correlation was calculated using Prism software, and the calculated R squared was 0.655.